Clinical trials: Myopericarditis
Myopericarditis, Myocarditis
Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old
Myopericarditis is a rare complication to messenger ribonucleic acid (mRNA) COVID-19 vaccines, especially in male adolescents and young adults. The risk in children 5-11 years old is unknown.
- Conditions
- Myopericarditis, Myocarditis, Vaccination; Complications, COVID-19 Pandemic
- Trial name
- NCT05186571
- Testing
- Pfizer-BioNTech mRNA COVID-19 vaccination
- Where
- Denmark
- Volunteers
- 350,000 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Myocarditis, Pericarditis
ACAM2000® Myopericarditis Registry
The purpose of this registry is to study the natural history of vaccination-related myocarditis and pericarditis and to assess possible risk factors for these conditions.
- Trial name
- NCT01395082
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Myocarditis
Incidence, Patient Characteristics and Outcome of Myocarditis After COVID-19 mRNA Vaccine
This study evaluates the incidence, patient characteristics and outcome of myocarditis after the COVID-19 mRNA vaccination in healthcare professionals.
- Trial name
- MACIS (NCT05438472)
- Testing
- data collection in healthcare professionals with COVID-19 mRNA vaccine booster
- Where
- Switzerland
- Volunteers
- 835 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Myopericarditis, Small Pox
Assessment of Myocarditis After Replication-Deficient Smallpox Immunization
This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA.
- Trial name
- PAMARDSI (NCT05513313)
- Testing
- JYNNEOS
- Volunteers
- 2,350 people, healthy volunteers welcome
- Sponsor
- Womack Army Medical Center